Study of HBS-301 for idiopathic hypersomnia
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new medication, HBS-301, in people with idiopathic hypersomnia (a condition causing excessive sleepiness without clear cause). It aims to see if the drug improves wakefulness and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a doctor-confirmed diagnosis of idiopathic hypersomnia with sleep tests on file from the last 10 years.
- You must have excessive daytime sleepiness that is moderate to very severe.
- If you take other medications for sleepiness or depression, the dose must be stable for at least 3 months and stay the same during the study.
- You cannot have used wake-promoting drugs like modafinil or stimulants as needed.
- Your hypersomnia cannot be caused by another medical condition.
- You must not have a history of certain heart problems or kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ORX750 for people with narcolepsy or idiopathic hypersomnia. You would need to stop your current sleepiness medicines to see if ORX750 helps reduce daytime sleepiness.
This trial tests whether low-dose sodium oxybate can improve symptoms in adults with idiopathic hypersomnia, a condition that causes excessive sleepiness. You’d likely be asked to pause this standard treatment briefly while baseline testing is completed, and you’d use reliable contraception during and after the study drug.
This study tests an investigational medication called TAK-360 for people with idiopathic hypersomnia (IH), a sleep disorder that causes excessive daytime sleepiness. The goal is to see if the drug can help reduce sleepiness and improve daily function.
This trial tests whether taking melatonin at night and using a bright light therapy device in the morning can improve excessive daytime sleepiness in people with idiopathic hypersomnia. It is a double-blind study, meaning neither you nor the doctors will know if you are getting the real treatment or a placebo.
This study tests a new medication called solriamfetol to see if it safely reduces excessive daytime sleepiness in people with idiopathic hypersomnia. You may receive the study drug or a placebo, and your sleepiness levels will be monitored to see if the treatment helps.
This study tests whether low sodium oxybate, a medication that improves alertness, can help reduce symptoms like dizziness and fatigue in people who have both idiopathic hypersomnia and POTS. You would stay on your current daytime medications, but some heart-related drugs may be paused temporarily before tests.
Hear when a new Idiopathic Hypersomnia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.